Tyrrell Frances, Stafford Cortney, Yakrus Mitchell, Youngblood Monica, Hill Andrew, Johnston Stephanie
1 Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Public Health Rep. 2017 Jan/Feb;132(1):56-64. doi: 10.1177/0033354916679989. Epub 2016 Dec 12.
We investigated data from US public health laboratories funded through the Centers for Disease Control and Prevention's Tuberculosis Elimination and Laboratory Cooperative Agreement to document trends and challenges in meeting national objectives in tuberculosis (TB) laboratory diagnoses.
We examined data on workload and turnaround time from public health laboratories' progress reports during 2009-2013. We reviewed methodologies, laboratory roles, and progress toward rapid detection of Mycobacterium tuberculosis complex through nucleic acid amplification (NAA) testing. We compared selected data with TB surveillance reports to estimate public health laboratories' contribution to national diagnostic services.
During the study period, culture and drug susceptibility tests decreased, but NAA testing increased. Public health laboratories achieved turnaround time benchmarks for drug susceptibility tests at lower levels than for acid-fast bacilli smear and identification from culture. NAA positivity in laboratories among surveillance-reported culture-positive TB cases increased from 26.6% (2355 of 8876) in 2009 to 40.0% (2948 of 7358) in 2013. Public health laboratories provided an estimated 50.9% (4285 of 8413 in 2010) to 57.2% (4210 of 7358 in 2013) of culture testing and 88.3% (6822 of 7727 in 2011) to 94.4% (6845 of 7250 in 2012) of drug susceptibility tests for all US TB cases.
Public health laboratories contribute substantially to TB diagnoses in the United States. Although testing volumes mostly decreased, the increase in NAA testing indicates continued progress in rapid M tuberculosis complex detection.
我们调查了由美国疾病控制与预防中心结核病消除和实验室合作协议资助的美国公共卫生实验室的数据,以记录结核病(TB)实验室诊断在实现国家目标方面的趋势和挑战。
我们检查了2009 - 2013年期间公共卫生实验室进度报告中的工作量和周转时间数据。我们回顾了方法、实验室作用以及通过核酸扩增(NAA)检测快速检测结核分枝杆菌复合群的进展。我们将选定的数据与结核病监测报告进行比较,以估计公共卫生实验室对国家诊断服务的贡献。
在研究期间,培养和药敏试验减少,但NAA检测增加。公共卫生实验室在药敏试验方面达到周转时间基准的水平低于抗酸杆菌涂片和培养鉴定。监测报告的培养阳性结核病病例中,实验室的NAA阳性率从2009年的26.6%(8876例中的2355例)增至2013年的40.0%(7358例中的2948例)。公共卫生实验室为美国所有结核病病例提供的培养检测估计占50.9%(2010年8413例中的4285例)至57.2%(2013年7358例中的4210例),药敏试验占88.3%(2011年7727例中的6822例)至94.4%(2012年7250例中的6845例)。
公共卫生实验室对美国的结核病诊断做出了重大贡献。尽管检测量大多下降,但NAA检测的增加表明在快速检测结核分枝杆菌复合群方面持续取得进展。